HSP90AB1 and melanoma: Additionally, HSP90 inhibition with an immunotherapeutic agent, ganetesip, enhanced the cytotoxic T cell killing of human-derived melanoma cells by upregulating the expression of interferon genes and potentiating the effect of anti-CTLA4 and anti-PD-1 therapies [252].